IGKV2-4: A Potential Drug Target and Biomarker (G28929)

Target Name: IGKV2-4

NCBI ID: G28929

Other Name(s): IGKV24 | immunoglobulin kappa variable 2-4 (pseudogene) | L13 | Immunoglobulin kappa variable 2-4 (pseudogene)

IGKV2-4: A Potential Drug Target and Biomarker

The IGKV2 gene family plays a crucial role in the regulation of intracellular signaling pathways, including the TGF-β pathway. This gene has four splice variants, IGKV2-1, IGKV2-2, IGKV2-3, and IGKV2-4, which differ in their last exon. IGKV2-4 is a potential drug target and biomarker due to its unique expression pattern in various tissues and its involvement in the TGF-β pathway.

Structure and Expression

IGKV2-4 is a 21-kDa protein that consists of 115 amino acid residues. It has a unique expression pattern, being expressed in the nuclei of various tissues, including brain, heart, skeletal muscles, and liver. In addition, IGKV2-4 is also expressed in various cell types, including cancer cells.

IGKV2-4 is involved in the regulation of TGF-β signaling pathway, which is a critical pathway involved in cell growth, differentiation, and survival. The TGF-β pathway is a complex signaling pathway that is activated by the binding of transforming growth factor-beta (TGF-β) to its receptor, Smad. Once activated, the TGF-β pathway regulates various cellular processes, including cell growth, differentiation, angiogenesis, and inflammation.

Drugs that target IGKV2-4 may have various therapeutic effects, including inhibition of TGF-β signaling pathway, which can lead to cell growth inhibition, apoptosis, and regression of cancer cells. Additionally, IGKV2-4 may also be involved in the regulation of cell adhesion, which is critical for the maintenance of tissue structure and the development of various diseases, such as cancer.

IGKV2-4 as a Biomarker

IGKV2-4 has also been identified as a potential biomarker for various diseases, including cancer. The IGKV2-4 gene has been shown to be overexpressed in various cancer types, including breast, ovarian, and colorectal cancer. This overexpression is associated with poor prognosis and increased cancer cell migration.

In addition, IGKV2-4 has been shown to be involved in the regulation of the TGF-β pathway, which is a critical pathway involved in cancer development and progression. Therefore, IGKV2-4 may be a useful biomarker for the evaluation of cancer risk and response to various therapies.

Conclusion

IGKV2-4 is a unique protein that has a crucial role in the regulation of intracellular signaling pathways, including the TGF-β pathway. Its unique expression pattern and involvement in the regulation of TGF-β signaling pathway make IGKV2-4 a potential drug target and biomarker. The potential therapeutic effects of IGKV2-4 may include inhibition of TGF-β signaling pathway, which can lead to cell growth inhibition, apoptosis, and regression of cancer cells. Additionally, IGKV2-4 may also be involved in the regulation of cell adhesion, which is critical for the maintenance of tissue structure and the development of various diseases, including cancer. Further studies are needed to fully understand the role of IGKV2-4 as a drug target and biomarker.

Protein Name: Immunoglobulin Kappa Variable 2-4 (pseudogene)

More Common Targets